Childhood leukemia remains a significant focus of cancer research, with ongoing efforts to discover novel therapies to improve survival rates and minimize long-term side effects. Recent advancements in targeted therapies, such as CAR T-cell therapy and small molecule inhibitors, have shown promise in treating relapsed or refractory leukemia. These therapies work by precisely targeting cancer cells, sparing normal cells and reducing toxicity. Additionally, research into genetic mutations and biomarkers has led to the identification of new therapeutic targets, enabling more personalized treatment strategies. The goal is to enhance cure rates while minimizing the impact of treatment on the child’s development and quality of life.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China